Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zevalin-Containing Conditioning for Allogeneic Stem Cell Transplantation in B-cell Malignancies
NCT01490723Phase 2Completed
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Jan 2013
- Primary completion
- Apr 2019
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ibritumomab tiuxetan in B cell lymphoma and leukemia, sponsored by University of Texas MD Anderson Cancer Center. Primary endpoint: Treatment-Related Mortality at 100 days. Started Jan 2013; status: completed.
02
Drugs
ibritumomab tiuxetan
03
Conditions
B cell lymphomaleukemia
Beyond the preview
Go deeper on NCT01490723.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01490723.